<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963882</url>
  </required_header>
  <id_info>
    <org_study_id>NACC</org_study_id>
    <nct_id>NCT03963882</nct_id>
  </id_info>
  <brief_title>NAC Followed by RH for the Treatment of LACC</brief_title>
  <official_title>Neoadjuvant Chemotherapy Followed by Radical Hysterectomy for the Treatment of Locally Advanced Cervical Cancer: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This cohort study is to evaluate the role of neoadjuvant chemotherapy (NAC) in the treatment
      of locally advanced cervical cancer (LACC). Sixty patients with LACC (FIGO 2009 stage IB2 to
      IIB) will be enrolled. After informed consents, they would accept the imaging evaluation of
      pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET). After
      excluding cases of distant metastasis, they will accept two cycles of NAC (paclitaxel 175
      mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks). Then a second MRI is performed
      to evaluate the imaging response. For patients achieving objective response, radical
      hysterectomy (RH, via laparoscopy or laparotomy) and an evaluation of pathologic response are
      performed. For patients without objective imaging response, the choice of concurrent
      chemoradiotherapy or radical hysterectomy will be discussed. After RH, adjuvant therapy will
      be given according to the RH pathologic results.

      The primary objectives consist of (1) the objective imaging response after NAC; (2) the
      objective pathologic response after RH.

      The secondary objectives consist of (1) disease-free survival and overall survival after
      various therapy modalities; (2) severe adverse effects of NAC; (3) the effects of NAC on the
      surgical outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>patients diagnosed with locally advanced cervical cancer of stage IB2 to IIB (FIGO 2009 system)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective pathologic response</measure>
    <time_frame>3 years</time_frame>
    <description>Objective pathologic response for patients with radical hysterectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective imaging response</measure>
    <time_frame>3 years</time_frame>
    <description>Objective imaging response for patients with neoadjuvant chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Disease-free survival for patients with various therapy modalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival for patients with various therapy modalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Severe adverse events of neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Locally Advanced Cervical Cancer</condition>
  <condition>Radical Hysterectomy</condition>
  <condition>Objective Response</condition>
  <condition>Laparoscopy</condition>
  <condition>Laparotomy</condition>
  <condition>Concurrent Chemoradiotherapy</condition>
  <condition>Adjuvant Therapy</condition>
  <condition>Systematic Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group A don't receive neoadjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group B receive neoadjuvant chemotherapy and achieve imaging response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept concurrent chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in group B receive neoadjuvant chemotherapy but don't achieve imaging response, and they accept radical hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Two cycles of neoadjuvant chemotherapy</intervention_name>
    <description>Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>First imaging evaluation</intervention_name>
    <description>First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Second imaging evaluation</intervention_name>
    <description>Second imaging evaluation consists of pelvic magnetic resonance imaging</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The third cycles of neoadjuvant chemotherapy</intervention_name>
    <description>The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RH</intervention_name>
    <description>Radical hysterectomy</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiochemotherapy</intervention_name>
    <description>Concurrent radiochemotherapy</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pathologic evaluation</intervention_name>
    <description>Pathologic evaluation for RH patients</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma
             of the uterine cervix

          -  FIGO stage IB2 to IIB

          -  Type II or III radical hysterectomy or trachelectomy

          -  Performance status of Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Aged 18 years to 45 years

          -  Well cardiopulmonary, liver and kidney functions for neoadjuvant chemotherapy

          -  Signed an approved informed consents

        Exclusion Criteria:

          -  Not satisfying any of the inclusion criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lilei@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

